To assess the interaction between OSA and CVD risk factors (hypertension, diabetes and dyslipidaemia), ORs of CVD for patients with AHI < 30 with (+) the risk factor, AHI>30 without (-) the risk factor, and AHI>30+the risk factor were referenced to patients with AHI < 30-the risk factor.
Results: The OR for CVD in patients with severe OSA was 1.44 (95% CI 1.17-1.78, P = 0.0006). In the absence of severe OSA, each risk factor increased the OR for CVD (see Table) . Compared to patients without severe OSA, those with severe OSA had greater CVD risk when there was co-existing hypertension, but not with co-existing diabetes or dyslipidemia.
Conclusion:
The crude ORs for CVD are increased in patients with severe OSA and patients with CVD risk factors. Severe OSA amplified this risk in patients with hypertension, but not diabetes or dyslipidaemia. The influence of other co-variates will be modelled. increases the risk of cardiovascular events, such as hypertension and ischemic heart disease (IHD). Patients with heart failure (HF) are at higher risk for sleep disorder; however, there is no documentation on NASD's association with HF to date. Therefore, our study aimed to determine whether NASD increases the risk of incident HF.
Methods: Using the outpatient and inpatient data from Taiwan's Longitudinal Health Insurance Database, we conducted a nationwide cohort study of patients with a first-time diagnosis of NASD in the year 2000 and followed up the risk of incident heart failure until December 31, 2013. We calculated risks and incidence ratios of HF for patients with NASD compared with the general population. The cumulative incidence of NASD and the subsequent risk of HF are assessed by the Kaplan-Meier method and Cox regression using a matched comparison cohort of HF patients without NASD.
Results: The NASD cohort had an adjusted hazard ratio (HR) of incident HF 23.6% higher than that of the cohort without NASD (95% CI = 1.164-1.308; P < 0.001). In the NASD population, the mean interval to HF in males and females were 5.02 AE 3.65 years and 5.02 AE 3.70 years, respectively. The Kaplan-Meier analysis indicated that after the seventh year, the incidence of HF was higher in the NASD cohort than in the control cohort till the end of the follow up. 
